bullish
Shanghai Henlius Biotech (2696 HK) - Thoughts on 2024 Results And the H Share Full Circulation
Xinyao has highlighted this Insight as a Top Pick
308 Views26 Mar 2025 08:55
Henlius saw profit 2nd year in a row, but investors question quality of profit. H Share Full Circulation has positive impact. Lin Lijun's increased holdings drive shares, aiming for higher exit price
What is covered in the Full Insight:
- Introduction to Henlius 2024 Performance
- Impact of H Share Full Circulation
- Product Revenue Analysis
- Internationalization Strategies and Future Outlook
- Investor Sentiment and Market Valuation
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Goldlion Holdings (533 HK) Privatization - Updates on Valuation Outlook Based on 2024 Results07 Apr 2025
- China Healthcare Weekly (Mar.2) - NewCo Model, Pfizer-Summit Deal, Henlius to Enter HK Stock Connect02 Mar 2025
- Shanghai Henlius Biotech (2696 HK)- LVC Is Betting on Higher Valuation Upside Due to Business Update12 Feb 2025
- Shanghai Henlius Biotech (2696 HK) - LVC Increased Its Holding of Henlius Again05 Feb 2025
x